CoChat

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

Open access

The DOI matches its Crossref record; 89 of the 91 references it cites were found in a registry or an index; 55 of the 76 sources its claims cite were checked for support.

Abstract

OBJECTIVE: This article examines the foundation of β-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment. RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations. RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of β-cell failure, natural history of β-cell failure, and impact of therapeutic interventions. CONCLUSIONS: β-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased β-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to (1) impact the natural history of β-cell failure; (2) identify and characterize genetic loci for T2D; (3) target β-cell signaling, metabolic, and genetic pathways to improve function/mass; (4) develop alternative sources of β-cells for cell-based therapy; (5) focus on metabolic environment to provide indirect benefit to β-cells; (6) improve understanding of the physiology of responses to bypass surgery; and (7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and β-cells.

Overview

CoChat Summary

TL;DR

This review/consensus report from an international expert meeting argues that progressive β-cell failure is central to type 2 diabetes, involving genetic/epigenetic changes and multiple stressors that lead to dysfunction, dedifferentiation, and death. It concludes existing therapies can improve β-cell function temporarily but generally do not arrest or reverse progression, with possible exception of gastric bypass, and identifies noninvasive β-cell mass measurement and stage-specific/combinatorial interventions as key research needs.

Key findings

  • Over 60 genetic loci have been convincingly associated with T2D, the great majority involved in some way in β-cell biology, but these variants explain only a small proportion of total genetic risk; approximately 50% of T2D-associated SNPs introduce or remove a CpG site, suggesting genetic-epigenetic interactions.
  • β-cell mass in T2D varies and overlaps with normal individuals, although current data suggest a 20–60% reduction; human β-cell mass varies three- to fivefold unrelated to age or BMI, and insulin sensitivity may vary as much as 10-fold. β-cell function and mass declines are not well correlated, while deteriorating β-cell function is tightly correlated with climbing glucose levels.
  • Multiple stressors are implicated: ER stress, metabolic/oxidative stress, amyloid/IAPP oligomers, islet inflammation (IL-1β antagonism can preserve some β-cell functional mass), and disrupted islet integrity. β-cell dedifferentiation has regained favor, and residual β-cells remain even in late disease.
  • Interventions show temporary β-cell functional improvement: in the DPP, greater baseline β-cell function and insulin sensitivity independently contributed to restoration of normal glucose tolerance; TZDs improved the oral disposition index; GLP-1–based therapies improve function during treatment but no meaningful persistent change follows withdrawal; RYGB produces disease remission in at least 80% of patients, with duration of diabetes and insulin use before surgery as strongest predictors.

Methods

  • Design: narrative review/consensus report from the October 2013 meeting “Beta Cell Failure in Type 2 Diabetes,” cosponsored by the Endocrine Society and the American Diabetes Association, assembling international experts to review the state of the science and identify research needs.
  • Data/sample: no primary experimental sample; synthesis of published human and animal studies, including genetics, epigenetics, islet biology, clinical trials, and surgical interventions.
  • Analysis: expert discussion and narrative synthesis; future research goals are presented in Table 1 (not included in the provided text).

Limitations

  • Stated: studies of epigenetics in T2D are severely limited by the small number of islets available from patients with T2D and by difficulty separating cause and effect in hyperglycemia; human β-cell mass measurement relies entirely on postmortem, cross-sectional assessments, and histomorphometric measurement of β-cell area, volume, and mass is often imprecisely defined and complicated by technical inconsistencies.
  • Stated: no study has established whether one pathogenic pathway dominates or can serve as a single major target; durability of β-cell functional improvements following therapy withdrawal remains challenging, and whether earlier intervention can alter the natural history of β-cell failure is unknown.
  • Evident from the text: as an expert consensus/narrative review, it does not describe a systematic search strategy or quantitative meta-analysis, and many cited mechanisms and genetic associations remain uncertain or require human validation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2337/dc14-0396

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Stressors on the β-cell in the pathogenesis of T2D. In the excessive nutritional state found in obesity, hyperglycemia and hyperlipidemia develop, increasing metabolic load coupled with concurrent inherent insulin resistance and chronic inflammation. The pancreatic islet response to this new environment is likely variable among individuals with differing genetic susceptibility but may include inflammatory stress, ER stress, metabolic and oxidative stress (e.g., glucotoxicity, lipotoxicity, and glucolipotoxicity), amyloid stress, and loss of islet cell integrity. If untreated, these interrelated stressors increase with time, promoting β-cell dysfunction (coupled with increased glucagon secretion) and ultimately loss of β-cell mass and possibly dedifferentiation that mark the onset of T2D.
Figure 1 Stressors on the β-cell in the pathogenesis of T2D. In the excessive nutritional state found in obesity, hyperglycemia and hyperlipidemia develop, increasing metabolic load coupled with concurrent inherent insulin resistance and chronic inflammation. The pancreatic islet response to this new environment is likely variable among individuals with differing genetic susceptibility but may include inflammatory stress, ER stress, metabolic and oxidative stress (e.g., glucotoxicity, lipotoxicity, and glucolipotoxicity), amyloid stress, and loss of islet cell integrity. If untreated, these interrelated stressors increase with time, promoting β-cell dysfunction (coupled with increased glucagon secretion) and ultimately loss of β-cell mass and possibly dedifferentiation that mark the onset of T2D.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

35 Valid · 6 Not valid · 7 Not checked · 26 Own results and interpretations

38 more claims · 21 with their cited sources checked

Create a free account to see all 74 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 27
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 89 references

Cited by

Items 301–400 of 462

Metadata

Authors
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C.
Affiliations
  • University of Geneva (CH)
  • University of Chicago (US)
  • Wake Forest University (US)
  • Albert Einstein College of Medicine (US)
  • Lund University (SE)
  • Indiana University Indianapolis (US)
  • Vanderbilt University (US)
  • Columbia University (US)
  • Joslin Diabetes Center (US)
Corresponding author
  • Halban, Philippe A.
  • Polonsky, Kenneth S.
Venue
Diabetes Care
Published
2014-05-10
Volume
37
Issue
6
Pages
1751-1758
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2142418958
Cited by
460
References
91
Citations by year
2026: 23 · 2025: 27 · 2024: 30 · 2023: 38 · 2022: 41 · 2021: 37 · 2020: 49 · 2019: 50 · 2018: 46 · 2017: 57 · 2016: 29 · 2015: 30 · 2014: 3
FWCI
7.49
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • American Diabetes Association
  • Eli Lilly and Company
  • Sanofi
  • University of Pennsylvania
  • University of Washington
  • University of Exeter
  • Vrije Universiteit Amsterdam
  • Lunds Universitet
  • Novo Nordisk
  • Università di Pisa
  • Novo Nordisk Fonden (NNF11OC1014546)
  • National Institutes of Health (UL1TR000430)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082590, P30DK020593, P30DK020595)
  • National Center for Advancing Translational Sciences
  • Children's Hospital of Pittsburgh
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
beta-cell failure, type 2 diabetes, beta-cell dysfunction, beta-cell mass, genetic susceptibility, diabetes prevention, diabetes treatment, genetic loci, cell therapy, bariatric surgery, circulating factors
MeSH terms
Congresses as Topic, Diabetes Mellitus, Type 2, Expert Testimony, Humans, Signal Transduction, Genetic Predisposition to Disease, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.